Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era

Anthony Mato, Jordan Jahnke, Pengxiang Li, Maneesha Mehra, Vrushab P. Ladage, Michelle Mahler, Scott Huntington, and Jalpa A. Doshi

Disclosures: At the time of the study, A.M. reported having received research funding and consultancy fees from Gilead, AbbVie, Pharmacycics, and TG Therapeutics; research funding from Acerta, Regeneron, Portola, and DTRM; and consultancy fees from Janssen, elgene, and Kite. At the time of our study, M.M. and M.M. were under the employment of Johnson & Johnson and held stock in Johnson & Johnson. S.H. reported receiving honoraria from Pharmacycics and consulting and traveling fees from Celgene and Janssen. J.A.D. reported serving as a consultant for Alkermes, Forest Laboratories (now Allergan), Ironwood Pharmaceuticals, Shire, and Vertex Pharmaceuticals; and had received research funding from AbbVie, Biogen, 18 Humana, Janssen, PhRMA, Pfizer, Regeneron, Sanofi, and the National Pharmaceutical Council. J.A.D.’s spouse holds stock in Merck and Pfizer. J.J., P.L., and V.P.L. have no conflicts to report.

Contributions: A.M., J.A.D., S.H., and P.L. conceived and designed the study; J.J. and P.L. performed the statistical analysis; and all authors interpreted the data, wrote the manuscript, and critically reviewed the final version of the manuscript.